For Investors

As a small research pharmaceutical company, our business model for revenue generation and value creation is to identify intellectual property (IP), invest in, conduct, and then complete the required research and development (R&D) of the identified IP candidates so that an FDA investigational new animal drug application (IAND) or investigational new drug application (IND) are obtained. The company then either licenses the right to manufacture and sell each product to earn fixed and per-unit royalties at standard industry rates, or sells the IP outright. Therapeutic Vision’s unique compounds developed to date have both veterinary and human potential.

The development of Kinostat® and the topical nutraceutical antioxidant for humans are the near-term focus of Therapeutic Vision. Kinostat® has received provisional FDA approval for canine veterinary marketing pending completion of the chemical manufacture and control (CMC) procedures. With immediate CMC funding, Kinostat® will be launched in 2026 for the prevention of cataract in diabetic dogs. The drug will then be transitioned as KinoStat® for the human diabetic market ($4.3 billion global market) by 2028 for the treatment of diabetic keratopathy-associated dry eye formation, normalization of corneal wound healing and corneal ulcers, and the safe implementation of LASIK surgery. The global market for diabetic keratopathy is growing due to the rising prevalence of diabetes and the associated eye diseases, with the market projected to reach $16.92 billion by 2033.

Currently, our antioxidant nutraceutical is an FDA-sanctioned over-the-counter (OTC) device for animals and is on the market, earning royalties via a license from Aventix Animal Health. Following reformulation for humans, the nutraceutical antioxidant TheraVision Eye Health can be on the human market for dry eye disease ($3.4 billion global market) by 2027.

In preclinical development, our Multifunctional Redox Modulators (MFRMsTM), represent a new class of orally active neuroprotective small molecules for preserving vision, hearing, and cognition. MFRMs address both oxidative stress and the cellular imbalance of iron, copper, and zinc transition metals and mitochondrial dysfunction that are linked to neurodegeneration. MFRMs are distinct from the numerous antioxidant supplements and chelators that have failed in clinical studies to address neuroprotection. Our synthetic MFRMs possess a unique structure that allows them to independently scavenge free radicals and independently selectively bind the transition metals iron, copper, or zinc that are associated with numerous neurodegenerative diseases. In addition, their molecular structure allows them to attain therapeutic levels in the target tissues of the eye, inner ear, and brain when orally administered. Importantly, unlike many antioxidants that, at high concentrations themselves, can undergo autoxidation that potentially leads to their degradation and loss of effectiveness, the molecular structure of MFRMs prevents autoxidation activity. Preclinical studies show that these compounds delay oxidation-induced cataracts that are generated by gamma irradiation, UV light, and endoplasmic reticulum (ER) stress. As oral neuroprotective agents, MFRMs have been documented by electrophysiology, biochemistry, and histology to prevent retinal degeneration, cochlear hair cell loss, and neural function in noise and blast-induced hearing loss, blast-induced retinal function, and amyloid beta formation in the brain, retina, and lens. In vitro studies also show that MFRMs remove zinc from the neurotoxic amyloid beta-zinc complex to allow subsequent degradation of the remaining amyloid beta. MRFMs have both broad military and civilian applications, as well as selective application in companion pets.

Additionally, there are other progressive neurodegenerative diseases associated with oxidative stress and metal dyshomeostasis of iron, copper, and zinc that MFRMs may beneficially treat. These include Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease (HD) and Usher syndrome, where hearing and vision loss is accompanied by mental and behavioral disorders that include psychosis, autism, and schizophrenia-like symptoms, the global neuroprotective drugs market size was valued at $68.6 billion in 2024 and is expected to reach 127.1 billion by 2034 growing at a compound annual growth rate of 7.0% per year.